Targeted mast cell silencing protects against joint destruction and angiogenesis in experimental arthritis in mice

Arthritis and Rheumatism

Volumn 56, Issue 6, 2007, Pages 1806-1816

  Kneilling, Manfred ^a   Hültner, Lothar ^b   Pichler, Bernd J ^a,c   Mailhammer, Reinhard ^b   Morawietz, Lars ^d   Solomon, Samuel ^e   Eichner, Martin ^a   Sabatino, Joseph ^b   Biedermann, Tilo ^a   Krenn, Veit ^d   Weber, Wolfgang A ^c   Illges, Harald ^e,f   Haubner, Roland ^c,g   Röcken, Martin ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY OF KONSTANZ   (Germany)

^f BONN RHEIN SIEG UNIVERSITY OF APPLIED SCIENCES   (Germany)

^g INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ACTIN; AUTOANTIBODY; CROMOGLYCATE DISODIUM; EOSIN; GLUCOSE 6 PHOSPHATE ISOMERASE; HEMATOXYLIN; SALBUTAMOL; VITRONECTIN RECEPTOR; ANTIIDIOTYPIC ANTIBODY; CYCLIC AMP;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; FEMALE; GENE SILENCING; GIEMSA STAIN; JOINT DESTRUCTION; MAST CELL; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR UPREGULATION; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; ANIMAL; ARTHROPATHY; BAGG ALBINO MOUSE; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG EFFECT; IMMUNOLOGY; MOUSE MUTANT; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ALBUTEROL; ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ARTHRITIS, RHEUMATOID; CROMOLYN SODIUM; CYCLIC AMP; DISEASE MODELS, ANIMAL; FEMALE; GLUCOSE-6-PHOSPHATE ISOMERASE; INTEGRIN ALPHAVBETA3; JOINT DISEASES; MAST CELLS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, MUTANT STRAINS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 34447529108     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22602     Document Type: Article

References (41)

1. Secor VH, Secor WE, Gutekunst CA, Brown MA. Mast cells are essential for early onset and severe disease in a murine model of multiple sclerosis. J Exp Med 2000;191:813-22.
2. Biedermann TM, Kneilling R, Mailhammer K, Maier CA, Sander G, Kollias SL, et al. Mast cells control neutrophil recruitment during T cell-mediated delayed-type hypersensitivity reactions through tumor necrosis factor and macrophage inflammatory protein 2. J Exp Med 2000;192:1441-52.
3. Lee DM, Friend DS, Gurish MF, Benoist C, Mathis D, Brenner MB. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science 2002;297:1689-92.
4. Echtenacher B, Mannel DN, Hultner L. Critical protective role of mast cells in a model of acute septic peritonitis. Nature 1996;381: 75-7.
5. Jiang WY, Chattedee AD, Raychaudhuri SP, Raychaudhuri SK, Farber EM. Mast cell density and IL-8 expression in nonlesional and lesional psoriatic skin. Int J Dermatol 2001;40:699-703.
6. Charlesworth EN. The role of basophils and mast cells in acute and late reactions in the skin. Allergy 1997;52:31-43.
7. Crisp AJ, Chapman CM, Kirkham SE, Schiller AL, Krane SM. Articular mastocytosis in rheumatoid arthritis. Arthritis Rheum 1984;7:845-51.
8. Rocken M, Hultner L. Heavy functions for light chains. Nat Med 2002;8:668-70.
9. Godfrey HP, Ilardi C, Engber W, Graziano FM. Quantitation of human synovial mast cells in rheumatoid arthritis and other rheumatic diseases. Arthritis Rheum 1984;27:852-6.
10. Malone DG, Wilder RL, Saavedra-Delgado AM, Metcalfe DD. Mast cell numbers in rheumatoid synovial tissues: correlations with quantitative measures of lymphocytic infiltration and modulation by antiinflammatory therapy. Arthritis Rheum 1987;30: 130-7.
11. Shin K, Gurish MF, Friend DS, Pemberton AD, Thornton EM, Miller HR, et al. Lymphocyte-independent connective tissue mast cells populate murine synovium. Arthritis Rheum 2006;54: 2863-71.
12. Binstadt BA, Patel PR, Alencar H, Nigrovic PA, Lee DM, Mahmood U, et al. Particularities of the vasculature can promote the organ specificity of autoimmune attack. Nat Immunol 2006;7: 284-92.
13. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell 1996;85:307-10.
14. Brennan FM, Maini RN, Feldmann M. Role of pro-inflammatory cytokines in rheumatoid arthritis. Springer Semin Immunopathol 1988;20:133-47.
15. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-61.
16. Zvaifler NJ, Firestein GS. Pannus and pannocytes: alternative models of joint destruction in rheumatoid arthritis. Arthritis Rheum 1994;37:783-9.
17. Kouskoff V, Korganow AS, Duchatelle V, Degott C, Benoist C, Mathis D. Organ-specific disease provoked by systemic autoimmunity. Cell 1996;87:811-22.
18. Korganow AS, Ji H, Mangialaio S, Duchatelle V, Pelanda R, Martin T, et al. From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity 1999;10:451-61.
19. Matsumoto I, Staub A, Benoist C, Mathis D. Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science 1999;286:1732-5.
20. Schaller M, Burton DR, Ditzel HJ. Autoantibodies to GPI in rheumatoid arthritis: linkage between an animal model and human disease. Nat Immunol 2001;2:746-53.
21. Zimmerman HJ, Schwartz MA, Boley LE, West M. Comparative serum enzymology. J Lab Clin Med 1965;66:961-72.
22. Maccioni M, Zeder-Lutz G, Huang H, Ebel C, Gerber P, Hergueux J, et al. Arthritogenic monoclonal antibodies from K/BxN mice. J Exp Med 2002;195:1071-7.
23. Eisenberg R, Albert D. B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus. Nat Clin Pract Rheumatol 2006;2:20-7.
24. Eisenberg R, Looney RJ. The therapeutic potential of anti-CD20 "what do B-cells do?". Clin Immunol 2005;117:207-13.
25. Solomon S, Rajasekaran N, Jeisy-Walder E, Snapper SB, Illges H. A crucial role for macrophages in the pathology of K/BxN serum-induced arthritis. Eur J Immunol 2005;35:3064-73.
26. Haubner R, Kuhnast B, Mang C, Weber WA, Kessler H, Wester HJ, et al. [18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem 2004;15: 61-9.
27. Haubner R, Wester HJ, Weber WA, Mang C, Ziegler SI, Goodman SL, et al. Noninvasive imaging of α(v)β3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 2001;61:1781-5.
28. Ziegler SI, Pichler BJ, Boening G, Rafecas M, Pimpl W, Lorenz E, et al. A prototype high-resolution animal positron tomograph with avalanche photodiode arrays and LSO crystals. Eur J Nucl Med 2001;28:136-43.
29. Koch AE. Angiogenesis as a target in rheumatoid arthritis. Ann Rheum Dis 2003;62 Suppl 2:ii60-7.
30. Cheresh DA, Stupack DG. Integrin-mediated death: an explanation of the integrin-knockout phenotype? Nat Med 2002;8:193-4.
31. Koning GA, Schiffelers RM, Wauben MH, Kok RJ, Mastrobattista E, Molema G, et al. Targeting of angiogenic endothelial cells at sites of inflammation by dexamcthasone phosphate-containing RGD peptide liposomes inhibits experimental arthritis. Arthritis Rheum 2006;54:1198-208.
32. Pichler BJ, Kneilling M, Haubner R, Braumuller H, Schwaiger M, Rocken M, et al. Imaging of delayed-type hypersensitivity reaction by PET and 18F-galacto-RGD. J Nucl Med 2005;46:184-9.
33. Malfait AM, Malik AS, Marinova-Mutafchieva L, Butler DM, Maini RN, Feldmann M. The β2-adrenergic agonist salbutamol is a potent suppressor of established collagen-induced arthritis: mechanisms of action. J Immunol 1999;162:6278-83.
34. Lichtenstein LM, Gillespie E. Inhibition of histamine release by histamine controlled by H2 receptor. Nature 1973;244:287-8.
35. Viscardi RM, Hasday JD, Gumpper KF, Taciak V, Campbell AB, Palmer TW. Cromolyn sodium prophylaxis inhibits pulmonary proinflammatory cytokines in infants at high risk for bronchopulmonary dysplasia. Am J Respir Crit Care Med 1997;156:1523-9.
36. Ghoreschi K, Thomas P, Breit S, Dugas M, Mailhammer R, van Eden W, et al. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat Med 2003;9:40-6.
37. Biedermann T, Mailhammer R, Mai A, Sander C, Ogilvie A, Brombacher F, et al. Reversal of established delayed type hypersensitivity reactions following therapy with IL-4 or antigen-specific Th2 cells. Eur J Immunol 2001;31:1582-91.
38. Biedermann T, Zimmermann S, Himmelrich H, Gumy A, Egeter O, Sakrauski AK, et al. IL-4 instructs TH1 responses and resistance to Leishmania major in susceptible BALB/c mice. Nat Immunol 2001;2:1054-60.
39. Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM. Th17: an effector CD4 T cell lineage with regulatory T cell tics. Immunity 2006;24:677-88.
40. Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, Kudo T, et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003;101:2620-7.
41. Ryu S, Lee JH, Kim SI. IL-17 increased the production of vascular endothelial growth factor in rheumatoid arthritis synoviocytes. Clin Rheumatol 2006;25:16-20.